Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance

AbbVie IncTrade
VanEck Rare Earth/Strategic MetalsTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs VanEck Rare Earth/Strategic Metals — how do they compare? AbbVie Inc trades at $248.69 (market cap $441.94B), while VanEck Rare Earth/Strategic Metals trades at $78. The key difference: AbbVie Inc pays a 2.77% dividend while VanEck Rare Earth/Strategic Metals pays none, and AbbVie Inc is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.

ABBVREMX
Market Cap
$441.94B
Sector
HealthSector/Thematic
52-Week High
$263.58$109.53
52-Week Low
$197.38$56.60
Enterprise Value
$506.19B
Dividend Yield
2.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

VanEck Rare Earth/Strategic Metals

REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $77.04, up 4.93% in the past 24 hours, reflecting strong momentum amid bullish technical signals. The ETF's high volatility (~50% annualized) and exposure to rare earth metals, critical for technology and defense, align with recent U.S. policy shifts to secure supply chains. However, key financial ratios like P/E and P/S are unavailable, limiting fundamental clarity. Support levels are clustered near $76-$77, with resistance at $78-$79, indicating a tight trading range.

Outlook hinges on geopolitical trends favoring rare earth independence from China, but risks include extreme volatility and China-dominated holdings. Analyst sentiment is mixed, with technical indicators suggesting near-term strength but overbought conditions. Investors should weigh the ETF's strategic theme against its suitability for conservative portfolios.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About VanEck Rare Earth/Strategic Metals

REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.

Read more on REMX